

# CÃ©line Pinheiro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4638910/publications.pdf>

Version: 2024-02-01

60  
papers

3,249  
citations

182225

30  
h-index

182931

54  
g-index

62  
all docs

62  
docs citations

62  
times ranked

4389  
citing authors

#	ARTICLE	IF	CITATIONS
1	Expression of Glycolysis-Related Proteins in Cancer of Unknown Primary Origin. <i>Frontiers in Oncology</i> , 2021, 11, 682665.	1.3	6
2	MCT1 expression is independently related to shorter cancer-specific survival in clear cell renal cell carcinoma. <i>Carcinogenesis</i> , 2021, 42, 1420-1427.	1.3	4
3	Targeting lactate production and efflux in prostate cancer. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165894.	1.8	17
4	The Quality of Pap Smears from the Brazilian Cervical Cancer Screening Program According to the Human Development Index. <i>Cancer Prevention Research</i> , 2020, 13, 299-308.	0.7	2
5	The Warburg Effect Is Associated With Tumor Aggressiveness in Testicular Germ Cell Tumors. <i>Frontiers in Endocrinology</i> , 2019, 10, 417.	1.5	28
6	Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma – MCT1 as potential target in diffuse large B cell lymphoma. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 303-318.	2.1	34
7	CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy. <i>BMC Cancer</i> , 2019, 19, 1173.	1.1	15
8	The clinicopathological significance of monocarboxylate transporters in testicular germ cell tumors. <i>Oncotarget</i> , 2018, 9, 20386-20398.	0.8	9
9	Trend analysis of the quality indicators for the Brazilian cervical cancer screening programme by region and state from 2006 to 2013. <i>BMC Cancer</i> , 2018, 18, 126.	1.1	21
10	Monocarboxylate transporter 1 is a key player in glioma–endothelial cell crosstalk. <i>Molecular Carcinogenesis</i> , 2017, 56, 2630-2642.	1.3	31
11	GLUT1 expression in pediatric adrenocortical tumors: a promising candidate to predict clinical behavior. <i>Oncotarget</i> , 2017, 8, 63835-63845.	0.8	8
12	Significance of glycolytic metabolism-related protein expression in colorectal cancer, lymph node and hepatic metastasis. <i>BMC Cancer</i> , 2016, 16, 535.	1.1	47
13	Prognostic significance of monocarboxylate transporter expression in oral cavity tumors. <i>Cell Cycle</i> , 2016, 15, 1865-1873.	1.3	35
14	The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4. <i>Cell Cycle</i> , 2016, 15, 1462-1470.	1.3	66
15	Reprogramming energy metabolism and inducing angiogenesis: co-expression of monocarboxylate transporters with VEGF family members in cervical adenocarcinomas. <i>BMC Cancer</i> , 2015, 15, 835.	1.1	29
16	Impact of an Educational Hands-on Project on the Antimicrobial, Antitumor and Anti-Inflammatory Properties of Plants on Portuguese Students’s Awareness, Knowledge, and Competences. <i>International Journal of Environmental Research and Public Health</i> , 2015, 12, 2437-2453.	1.2	6
17	Historical Analysis of the Brazilian Cervical Cancer Screening Program from 2006 to 2013: A Time for Reflection. <i>PLoS ONE</i> , 2015, 10, e0138945.	1.1	36
18	Monocarboxylate transport inhibition potentiates the cytotoxic effect of 5-fluorouracil in colorectal cancer cells. <i>Cancer Letters</i> , 2015, 365, 68-78.	3.2	65

#	ARTICLE	IF	CITATIONS
19	Targeting lactate transport suppresses <i>in vivo</i> breast tumour growth. <i>Oncotarget</i> , 2015, 6, 19177-19189.	0.8	92
20	Metabolic reprogramming: a new relevant pathway in adult adrenocortical tumors. <i>Oncotarget</i> , 2015, 6, 44403-44421.	0.8	34
21	Glucose addiction in cancer therapy: advances and drawbacks. <i>Current Drug Metabolism</i> , 2015, 16, 221-242.	0.7	50
22	The basal epithelial marker P-cadherin associates with breast cancer cell populations harboring a glycolytic and acid-resistant phenotype. <i>BMC Cancer</i> , 2014, 14, 734.	1.1	25
23	Lactate transporters and vascular factors in HPV-induced squamous cell carcinoma of the uterine cervix. <i>BMC Cancer</i> , 2014, 14, 751.	1.1	23
24	Differential sensitivities to lactate transport inhibitors of breast cancer cell lines. <i>Endocrine-Related Cancer</i> , 2014, 21, 27-38.	1.6	54
25	Characterization of monocarboxylate transporters (MCTs) expression in soft tissue sarcomas: distinct prognostic impact of MCT1 sub-cellular localization. <i>Journal of Translational Medicine</i> , 2014, 12, 118.	1.8	29
26	Monocarboxylate transporters as targets and mediators in cancer therapy response. <i>Histology and Histopathology</i> , 2014, 29, 1511-24.	0.5	87
27	Characterization of monocarboxylate transporter activity in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 11780.	1.4	31
28	Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. <i>Neuro-Oncology</i> , 2013, 15, 172-188.	0.6	208
29	Assessing the Impact of a School Intervention to Promote Students' Knowledge and Practices on Correct Antibiotic Use. <i>International Journal of Environmental Research and Public Health</i> , 2013, 10, 2920-2931.	1.2	28
30	A Hospital Based Cohort Study of Colorectal Cancer Cases Treated at Braga Hospital, Northern Portugal. , 2013, 03, .		1
31	Lactate-Induced IL-8 Pathway in Endothelial Cells"Letter. <i>Cancer Research</i> , 2012, 72, 1901-1902.	0.4	5
32	453 Regulation of the Metabolic Profile of Breast Cancer Cells by Hypoxia. <i>European Journal of Cancer</i> , 2012, 48, S108-S109.	1.3	0
33	462 MCT1 Plasma Membrane Expression is Associated to Hypoxic Regions in Glioblastomas. <i>European Journal of Cancer</i> , 2012, 48, S111.	1.3	0
34	469 Role of Monocarboxylate Transporters (MCTs) in the Regulation of the Metabolic Profile of Cervical Cancer Cells by Hypoxia. <i>European Journal of Cancer</i> , 2012, 48, S113.	1.3	0
35	903 Exploring the "Warburg Effect" for Cancer Therapy " Targeting Lactate Transport in Cervical Cancer. <i>European Journal of Cancer</i> , 2012, 48, S219.	1.3	0
36	CD147 immunohistochemistry discriminates between reactive mesothelial cells and malignant mesothelioma. <i>Diagnostic Cytopathology</i> , 2012, 40, 478-483.	0.5	31

#	ARTICLE	IF	CITATIONS
37	Co-expression of monocarboxylate transporter 1 (MCT1) and its chaperone (CD147) is associated with low survival in patients with gastrointestinal stromal tumors (GISTs). <i>Journal of Bioenergetics and Biomembranes</i> , 2012, 44, 171-178.	1.0	51
38	Butyrate activates the monocarboxylate transporter MCT4 expression in breast cancer cells and enhances the antitumor activity of 3-bromopyruvate. <i>Journal of Bioenergetics and Biomembranes</i> , 2012, 44, 141-153.	1.0	60
39	Role of monocarboxylate transporters in human cancers: state of the art. <i>Journal of Bioenergetics and Biomembranes</i> , 2012, 44, 127-139.	1.0	330
40	SLC16A1 (solute carrier family 16, member 1 (monocarboxylic acid transporter 1)). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2011, , .	0.1	0
41	Impact of EGFR Genetic Variants on Glioma Risk and Patient Outcome. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2610-2617.	1.1	37
42	Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. <i>BMC Cancer</i> , 2011, 11, 312.	1.1	147
43	GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression. <i>Histology and Histopathology</i> , 2011, 26, 1279-86.	0.5	126
44	Monocarboxylate transporter 1 is upregulated in basal-like breast carcinoma. <i>Histopathology</i> , 2010, 56, 860-867.	1.6	168
45	Expression of Monocarboxylate Transporters 1, 2, and 4 in Human Tumours and Their Association with CD147 and CD44. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-7.	3.0	144
46	349 Monocarboxylate transporter 1 as a potential therapeutic target in glioblastomas. <i>European Journal of Cancer</i> , Supplement, 2010, 8, 111.	2.2	0
47	Monocarboxylate Transporters 1 and 4 Are Associated with CD147 in Cervical Carcinoma. <i>Disease Markers</i> , 2009, 26, 97-103.	0.6	52
48	Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas. <i>British Journal of Cancer</i> , 2009, 101, 973-982.	2.9	104
49	Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma. <i>BMC Cancer</i> , 2009, 9, 212.	1.1	52
50	Portuguese students' knowledge of antibiotics: a cross-sectional study of secondary school and university students in Braga. <i>BMC Public Health</i> , 2009, 9, 359.	1.2	50
51	The prognostic value of CD147/EMMPRIN is associated with monocarboxylate transporter 1 co-expression in gastric cancer. <i>European Journal of Cancer</i> , 2009, 45, 2418-2424.	1.3	78
52	Characterization of Monocarboxylate Transporters' expression in prostate carcinoma. <i>Microscopy and Microanalysis</i> , 2009, 15, 17-18.	0.2	1
53	Monocarboxylate transporters 1 and 4 are associated with CD147 in cervical carcinoma. <i>Disease Markers</i> , 2009, 26, 97-103.	0.6	48
54	Peritumoural, but not intratumoural, lymphatic vessel density and invasion correlate with colorectal carcinoma poor-outcome markers. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008, 452, 133-138.	1.4	24

#	ARTICLE	IF	CITATIONS
55	Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008, 452, 139-146.	1.4	211
56	Increasing Expression of Monocarboxylate Transporters 1 and 4 Along Progression to Invasive Cervical Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2008, 27, 568-574.	0.9	84
57	Cyclooxygenase-2 and Epidermal Growth Factor Receptor Expressions in Different Histological Subtypes of Cervical Carcinomas. <i>International Journal of Gynecological Pathology</i> , 2007, 26, 235-241.	0.9	21
58	How useful is the assessment of lymphatic vascular density in oral carcinoma prognosis?. <i>World Journal of Surgical Oncology</i> , 2007, 5, 140.	0.8	30
59	Lymphatic vessel density and epithelial D2-40 immunoreactivity in pre-invasive and invasive lesions of the uterine cervix. <i>Gynecologic Oncology</i> , 2007, 107, 45-51.	0.6	43
60	EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. <i>Journal of Pathology</i> , 2006, 209, 445-453.	2.1	230